A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

The primary objective of the study is to assess the relative bioavailability of omaveloxolone capsules when administered as either intact capsules or capsule contents sprinkled over low-fat, non-Greek yogurt in healthy adult participants. The secondary objective of the study is to evaluate the safety and tolerability of a single dose of omaveloxolone administered as either an intact capsule or sprinkled over low-fat, non-Greek yogurt in healthy adult participants.

Key Inclusion Criteria:

• Body Mass Index (BMI) at screening between 18 and 32 kilograms per meter square (kg/m^2), inclusive
• Must be in good health as determined by the Investigator, based on medical history and Screening evaluations

Key Exclusion Criteria:

• History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease
• History of, or ongoing, malignant disease (with exceptions for completely excised basal cell carcinomas and squamous cell carcinomas cured at least 1 year prior to Day -1)
• Systolic blood pressure > 150 millimeters of mercury (mmHg) or < 90 mmHg after sitting for 5 minutes
• Clinically significant, as determined by the Investigator, 12-lead electrocardiogram (ECG) abnormalities
• Corrected QT interval > 450 milliseconds (ms) for males and > 460 ms for females
• Positive diagnostic tuberculosis test result within 30 days of Enrollment
• History of, or positive test result for human immunodeficiency virus (HIV)
• History of hepatitis C infection or positive test result for hepatitis C virus antibody (HCV Ab)
• Current hepatitis B infection
• Any value for alanine aminotransferase, aspartate aminotransferase, bilirubin, or serum creatinine above the upper limit of normal
• Platelets below the lower limit of normal
• Any clinically significant value out of normal range for total white blood cells
• Prior exposure to the study treatment
• Use of prescription medication (excluding oral contraceptives and hormone replacement therapy), over-the-counter oral medication that alters hepatic or renal clearance, or nutraceuticals within 28 days prior to Day -1
• Use of other over-the-counter oral medication, vitamins, dietary supplements, or antacids within 14 days prior to Day -1

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply